2009-01-10 01:17:02 -

Research and Markets (www.researchandmarkets.com/research/87e8ab/canada_pharmaceuti) has announced the addition of the "Canada Pharmaceuticals and Healthcare Report Q4 2008" report to their offering.


The Canadian drug market should record reasonable growth in local currency terms over the forecast period, reaching a value of US$29.3bn in 2012. Fluctuations in the exchange rate, however, will mean that there will be greater variations

in the pharmaceutical market in US dollar terms. Overall, growth will be slower than over the previous five years, owing to government cost-containment measures, aimed at curbing Canada's high consumption. Patent expiries should have the dual impact of suppressing growth in the patented-drug sector while driving the generics sector forward. Indeed, by 2012, we expect generic-drug expenditure to reach US$5.5bn.


The Canadian government is reportedly set to invest CAD1mn (US$0.99mn) to establish a network of pharmaceutical research centres that will assess the safety and effectiveness of drugs after they have been launched. The network will be a part of the Food and Consumer Safety Action Plan, which was launched by Canada in December 2007. We believe that research-based drugmakers are unlikely to welcome another layer of regulations in an already difficult operating environment


Meanwhile, the first approval of Swiss firm Basilea Pharmaceutica's anti-infective Zeftera (ceftobiprole) has highlighted the differences in regulatory agencies in the US and Canada. After reviewing the drug's dossier for nearly 12 months, the Canadian health ministry - Health Canada - was satisfied with the cephalosporin's safety, efficacy and quality of manufacture, and accordingly gave the green light for commercialisation. This was despite the US Food and Drug Administration (FDA) rejecting Zeftera in March 2008 and asking for a further assessment of the drug's clinical data.


Elsewhere, WellSpring Pharmaceutical, a North American-based pharmaceutical manufacturer expanded its consumer health product line by concluding a deal with McNeil Consumer Healthcare in Canada. Under the terms of the transaction, Wellspring has bought the US and Canadian rights to a number of over-the-counter (OTC) products. The Canadian drugs are Micatin, Gelusil and Glycerin Suppositories (glycerol + gelatin).


In our Q408 Business Environment Rankings for the Americas region, Canada has fallen from second to third place. The drop comes after we downgraded the country's pharmaceutical market forecast, while Puerto Rico has also improved its business environment in the quarter.


Key Topics Covered:


- Executive Summary 5
- Canada Pharmaceuticals And Healthcare Industry SWOT 6
- Canada Political SWOT 7
- Canada Economic SWOT 7
- Pharmaceutical Business Environment Ratings 8
- Table: Americas Pharmaceutical Business Environment Rating 8
- Limits Of Potential Returns 8
- Risks To Realisation Of Returns 9
- Canada - Market Summary 10
- Regulatory Regime11
- Pricing And Reimbursement Issues 14
- Ontario Invests In Drug Industry 16
- Industry Developments19
- Product Approvals And Launches 24
- Pharmaceutical Re-import Policy 26
- Company Activity 27
- National Pharmaceuticals Strategy 33
- Generics Sector 34
- Research And Development Sector 35
- Pharmacy Sector 37
- Industry Forecast Scenario 39
- Overall Market Forecast 39
- Sources 73
Companies Mentioned:


- Pfizer
- Merck & Co
- GlaxoSmithKline
- Sanofi-Aventis
- Novartis
- Apotex
For more information visit www.researchandmarkets.com/research/87e8ab/canada_pharmaceuti








Research and Markets

Laura Wood

Senior Manager

press@researchandmarkets.com

Fax from USA: 646-607-1907

Fax from rest of the world: +353-1-481-1716